GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Stemtech STEK · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 5 Nov 2026, in USD

About Stemtech

From its filings with the US Securities and Exchange Commission

SEC filings

Stemtech is based in Naples, Florida. Its shares trade on OTC under the ticker STEK. The SEC classifies its business as wholesale-drugs, proprietaries & druggists' sundries. In the fiscal year to 31 December 2025, it reported revenue of $2.9m and a net loss of $4.0m. At that date it held total assets of $3.1m and shareholders' equity of −$7.0m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
15 Sept 2014
Employees
45
Head office
4851 TAMIAMI TRAIL NORTH, NAPLES, FL, 34103
Classification
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Charles ArnoldChairman of the Board, Chief Executive Officer, since 2021$268,904
  • Mr. John MeyerPresident, Chief Operating Officer, Director, since 2021$229,526
  • Ms. Shrilakshmi VadlapatlaChief Financial Officer
  • Mr. Darryl GreenIndependent Director
  • Mr. Benjamin KaplanIndependent Director
  • Mr. John ThatchIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 45 full-time staff members in its operations.
  • Products like RCM System support the body's stem cell functions.
  • Stemflo MigraStem helps circulate stem cells into tissues for renewal.

Weaknesses

  • The firm has a small workforce of only 45 employees.
  • Operations are concentrated in the US headquarters in Naples Florida.
  • The company relies on independent distributors for international marketing reach.

Opportunities

  • Asia segment offers potential growth for international product distribution.
  • Latin America provides an expanding market for nutritional supplements.
  • North America remains a key segment for current sales volume.

Threats

  • Dependence on independent distributors may reduce direct market control.
  • International operations face regulatory challenges across different countries.
  • Competition in the nutritional supplements sector is likely intense.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.